EP3638696
NOTKUN Á ARGX-110 MÓTEFNI GEGN CD70 TIL AÐ MEÐHÖNDLA BRÁTT KYRNINGAHVÍTBLÆÐI
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
18.6.2018EP published:
6.3.2024EP application number:
18732064.3
EP translation filed:
2.4.2024Grant published:
15.5.2024EPO information:
European Patent Register
Max expiry date:
17.6.2038Expiry date:
17.6.2026Next due date:
30.6.2026
Title in English:
USE OF ANTI CD70 ANTIBODY ARGX-110 TO TREAT ACUTE MYELOID LEUKAEMIALanguage of the patent:
English
Timeline
Today
18.6.2018EP application
6.3.2024EP Publication
2.4.2024Translation submitted
15.5.2024Registration published
17.6.2026Expires
Owner
Name:
argenx BVAddress:
Industriepark-Zwijnaarde 7, 9052 Zwijnaarde (Ghent), BE
Name:
University of BernAddress:
Verwaltungsdirektion Hochschulstrasse 6, 3012 Bern, CH
Inventor
Name:
LEUPIN, NicolasAddress:
B-9052 Gent, BE
Name:
VAN ROMPAEY, LucAddress:
B-9052 Gent, BE
Name:
DE HAARD, HansAddress:
B-9052 Gent, BE
Name:
OCHSENBEIN, AdrianAddress:
3032 Hinterkappelen, CH
Name:
RIETHER, CarstenAddress:
3012 Bern, CH
Agent
Name:
Tego IP ehf.Address:
Pósthólf 8129, 128, Reykjavík,
Priority
Number:
201709677Date:
16.6.2017Country:
GB
Classification
Categories:
C07K 16/28, A61K 39/00
Annual fees
Number
Paid
Expires
Payer
Number: 7
Paid: 31.5.2024
Expires: 17.6.2025
Payer: Árnason Faktor ehf.
Number: 8
Paid: 12.6.2025
Expires: 17.6.2026
Payer: Árnason Faktor ehf.